GlassScriptPhysician profile
Betsy Weisz
NPI 1508838749
$2,535.22
in general payments reported to CMS, 2019-2025
21 companies · $316 in 2025
The $316 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $51.25 · 2021: $217 · 2022: $421 · 2023: $642 · 2024: $266 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $312.83 | 2019-2025 | Vaxneuvance, Enflonsia, Proquad |
| Ironshore Pharmaceuticals INC. | $281.70 | 2019-2023 | Jornay Pm |
| Corium, LLC | $269.21 | 2022-2023 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $221.86 | 2024-2025 | Dupixent |
| Supernus Pharmaceuticals, INC. | $203.14 | 2021-2022 | |
| Tris Pharma INC | $201.03 | 2019-2023 | Quillichew Er, Dyanavel Xr, Quillivant |
| Sanofi Pasteur INC. | $172.25 | 2023 | |
| Dermira, INC. | $122.63 | 2019 | |
| Novo Nordisk INC | $116.98 | 2024 | Wegovy |
| Glaxosmithkline, LLC. | $109.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.11 | 2025 | |
| Celgene Corporation | $83.39 | 2019 | |
| Neos Therapeutics, LP | $66.11 | 2019 | |
| Shire North American Group INC | $55.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.79 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $48.67 | 2019-2023 | Doc Band |
| Phadia US INC. | $35.15 | 2021-2024 | Immunocap |
| Adlon Therapeutics L.P. | $29.55 | 2020 | |
| Pfizer INC. | $22.59 | 2024 | |
| Alk-Abello, INC | $16.46 | 2023 | Odactra, Ragwitek, Grastek |
| Seqirus USA INC | $15.13 | 2023 | Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Weisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.